Biotech investor, operator & BD | Drug development | EIR @MSKCancerCenter | 🦋 rubensebas.bsky.social
New York, NY
- Tweets 3,274
- Following 2,193
- Followers 852
- Likes 2,901
Great piece on Tolerance Bio. It’s fantastic to see what the team has achieved in less than two years since we led the founding round
biobuzz.io/news/tolerance-bi…
75
Ruben Sebastian retweeted
Tolerance Bio has continued to strengthen its thymus-focused pipeline by picking up an anti-IL-33 drug from Tanabe Pharma. fiercebiotech.com/biotech/to…
4
15
3,293
Tolerance Bio expands its #thymus focused pipeline, now adding a clinical-stage anti-IL-33 antibody
This is the second clinical program with the recently licensed long-acting IL-7. Tolerance further broadens its leading pipeline targeting thymic biology
businesswire.com/news/home/2…
63
Great news from Minoryx! Major milestone for the cALD patient community.
NEZGLYAL® (leriglitazone), developed by Minoryx, is now approved in Europe as the first pharmacological treatment for cALD, a rare neurodegenerative disease.
minoryx.com/media/european-c…
80
Historic approval!
$RVMD
fda.gov/news-events/press-an…
1
2
288
Ruben Sebastian retweeted
I have to say, when Merck called me last night with the mRNA cancer vaccine news (embargoed, of course), I literally yelped in reaction.
Consider this: Between this spring's Revolution Medicines success with a KRAS-targeted drug and now Merck and Moderna's success with an mRNA neoantigen vaccine, 2026 will go down as one of the most consequential years in cancer treatment, ever.
Incredible.
97
468
4,235
422,149
Proud of former portfolio company Minoryx Therapeutics!
Leriglitazone (NEZGLYAL) receives a positive opinion from EMA for the treatment of cALD. Impressive achievement by a Barcelona born biotech with massive implications for the cALD patient community!
minoryx.com/media/leriglitaz…
2
289
Confirmed: Abbvie to acquire Apogee for $10.9 billion, strengthening its immunology franchise with $APGE portfolio of long-acting antibodies
Great day to be a holder of $APGE and $ABBV!
news.abbvie.com/2026-06-22-A…
110
Abbvie reportedly in advanced negotiations to acquire Apogee $APGE!
Scoop by @mroliverbarnes @FT
ft.com/content/cb5e94aa-1687…
3
252
Servier to acquire Edgewise muscular #dystrophy business for up to $2.65 billion
Includes sevasemten, an oral first-in-class fast skeletal myosin inhibitor. Currently in a pivotal cohort in Becker, and in Ph2 in #Duchenne
Proud holder $EWTX!
prnewswire.com/news-releases…
1
213
Personalized neoantigen mRNA vaccine (intismeran autogene) 5 year follow-up in metastatic melanoma reduced recurrence and death by 49% (on top of Keytruda)
#ASCO26 $MRK $MRNA
merck.com/news/moderna-and-m…
1
1
343
This is why we do what we do! Foundational research leads to novel medicines for the benefit of our patients. Congrats $RVMD, Brian Wolpin, @EileenMOReilly and everyone involved!
Today is a day to celebrate science, drug development and biotech! #ASCO26
1
9
407
Lilly to acquire Ajax for up to $2.3B. Its lead program (AJ1-11095) is a once-daily oral first-in-class type II #JAK2 inhibitor
Great story for the NYC #biotech ecosystem! Kudos to the founding scientists from @MSKCancerCenter, @nyuniversity & Schrodinger
prnewswire.com/news-releases…
1
123
Great news from Oruka $ORKA! ORKA-001, half-life extended IL-23p19 mAb, achieved 63.5% PASI 100 at week 16 in a Phase 2a #psoriasis trial
ir.orukatx.com/news-releases…
132
We’re witnessing impressive advances in pancreatic cancer! A pancreatic cancer mRNA vaccine shows a very strong and durable immune response in a Phase 1 trial. New 6-year data are being presented today at #AACR2026 @MSKCancerCenter
nbcnews.com/health/cancer/pa…
2
7
814
Lilly to acquire Kelonia to advance in vivo CAR-T cell therapies for $3.25 billion upfront and up to $7 billion
Kelonia's lead program is an i.v. gene therapy that generates anti-BCMA CAR-T cells in vivo and is currently in Ph1 for r/r multiple myeloma
investor.lilly.com/news-rele…
91
What a few days of M&A activity, with good friends involved.
- Today: Merck to acquire Terns (allosteric TKI, leukemia) for $6.7B
- Monday: Gilead to acquire Ouro (BCMA TCE, I&I) for $2.2B
- Last week: Novartis to acquire Synnovation’s SNV4818 (PI3Ki, breast cancer) for $3B
103
Belén Garijo, departing CEO of Merck KGaA, will take the helm at Sanofi as its new CEO starting in April 2026
sanofi.com/en/media-room/pre…
123
European biotech Agomab files for a Nasdaq IPO.
Will we see a surge of news post #JPM26? 🤔
bloomberg.com/news/articles/…
1
138